957 related articles for article (PubMed ID: 26091668)
21. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
[TBL] [Abstract][Full Text] [Related]
22. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
[TBL] [Abstract][Full Text] [Related]
23. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
[TBL] [Abstract][Full Text] [Related]
24. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
25. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
26. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
27. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
Lasica AB; Jaunmuktane Z; Fersht N; Kirkman MA; Dixon L; Hoskote C; Brandner S; Samandouras G
World Neurosurg; 2021 Jul; 151():e217-e233. PubMed ID: 33866029
[TBL] [Abstract][Full Text] [Related]
28. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
29. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.
Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W
Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
31. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
Olar A; Wani KM; Alfaro-Munoz KD; Heathcock LE; van Thuijl HF; Gilbert MR; Armstrong TS; Sulman EP; Cahill DP; Vera-Bolanos E; Yuan Y; Reijneveld JC; Ylstra B; Wesseling P; Aldape KD
Acta Neuropathol; 2015 Apr; 129(4):585-96. PubMed ID: 25701198
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
33. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
34. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
35. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
Aoki K; Suzuki H; Yamamoto T; Yamamoto KN; Maeda S; Okuno Y; Ranjit M; Motomura K; Ohka F; Tanahashi K; Hirano M; Nishikawa T; Shimizu H; Kitano Y; Yamaguchi J; Yamazaki S; Nakamura H; Takahashi M; Narita Y; Nakada M; Deguchi S; Mizoguchi M; Momii Y; Muragaki Y; Abe T; Akimoto J; Wakabayashi T; Saito R; Ogawa S; Haeno H; Natsume A
Cancer Res; 2021 Sep; 81(18):4861-4873. PubMed ID: 34333454
[TBL] [Abstract][Full Text] [Related]
36. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
37. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system.
Takei H; Shinoda J; Ikuta S; Maruyama T; Muragaki Y; Kawasaki T; Ikegame Y; Okada M; Ito T; Asano Y; Yokoyama K; Nakayama N; Yano H; Iwama T
J Neurosurg; 2019 Aug; 133(4):1010-1019. PubMed ID: 31419796
[TBL] [Abstract][Full Text] [Related]
39. Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review.
Bunevicius A; Miller J; Parsons M
Curr Oncol Rep; 2020 Sep; 22(12):120. PubMed ID: 32965568
[TBL] [Abstract][Full Text] [Related]
40. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.
Unruh D; Zewde M; Buss A; Drumm MR; Tran AN; Scholtens DM; Horbinski C
Sci Rep; 2019 Jun; 9(1):8946. PubMed ID: 31222125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]